Neuren’s products are related to a naturally occurring growth factor produced in the brain, which means they potentially are applicable to a wide range of conditions. The technology was invented at the University of Auckland.

Neuren’s lead drug, “NNZ-2566”, is being tested in Phase 2 clinical trials to treat 4 different conditions. Two trials are treating brain injury – severe and mild (concussion). Neuren receives funding from the US Army for these trials. The other two trials are treating the genetic disorders Rett Syndrome and Fragile X Syndrome, in which normal brain development is impeded. Rett Syndrome leads to profound disability and Fragile X Syndrome is the most common known cause of autism.

Each of the four conditions represents a large unserved market, with no drugs approved and few drugs in clinical development. Because these are serious medical conditions with unmet need, drugs being developed to treat them may qualify for favourable regulatory pathways. The FDA has granted “Fast Track” designation and “orphan drug” designation to Neuren for NNZ-2566 programs."